Sino Biopharmaceutical

Sino Biopharmaceutical Limited, commonly known as Sino Biopharmaceutical or SBP Group, is a pharmaceutical conglomerate headquartered in Hong Kong and operating primarily in mainland China. The company is listed on the Hong Kong Stock Exchange under ticker 1177.HK and has developed a broad pharmaceutical portfolio spanning chemical medicines and biopharmaceutical products. Its activities include research and development, manufacturing, commercialization, and sales of prescription medicines. The group serves several major therapeutic areas. Its portfolio and operating businesses are associated with oncology, liver diseases, respiratory-system diseases, surgery, and analgesia, among other fields. This gives the company a diversified position across hospital medicines and specialist treatments rather than a single-product or consumer-health focus. The group’s business model combines internally developed products with the capabilities of a network of operating subsidiaries and affiliated pharmaceutical companies. Principal subsidiaries identified in public reference material include Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Beijing Tide Pharmaceutical Co., Ltd., Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Jiangsu Chia Tai Qingjiang Pharmaceutical Co., Ltd., and invoX Pharma Limited. These entities support the group’s research, production, and commercial activities across different medicines and therapeutic categories. Sino Biopharmaceutical became a Hong Kong-listed company in 2000. Its subsequent inclusion in major market indexes reflected its growing profile among China-focused listed healthcare companies. It entered the MSCI Global Standard Indices and MSCI China Index in 2013, became a Hang Seng Index constituent in 2018, joined the Hang Seng China Enterprises Index in 2019, and was included in the Hang Seng Connect Biotech 50 Index and Hang Seng China (Hong Kong-listed) 25 Index in 2020. The company’s positioning is that of a large, research-oriented Chinese pharmaceutical group with capabilities across innovative medicines, biopharmaceuticals, and established chemical medicines. Publicly available reference material does not provide sufficient information here to establish a complete chronology of its founding management, detailed revenue mix, individual product launch dates, or current executive roster. Those details should be verified against the company’s latest annual report and regulatory filings.

Sino Biopharmaceutical Limited is a Hong Kong-listed pharmaceutical group whose operating footprint is concentrated in mainland China, with Hong Kong serving as its listed-company and corporate base. The group is also referred to as SBP Group. Its business is organized around the development, production, and sale of pharmaceutical products, including chemical medicines and biopharmaceuticals. The company was listed on the Hong Kong Stock Exchange in 2000. The listing established the group as a publicly traded pharmaceutical enterprise and provided the capital-market platform through which its business has been represented to investors. Public reference material identifies the group’s principal operating subsidiaries as Chia Tai Tianqing Pharmaceutical Group, Beijing Tide Pharmaceutical, Nanjing Chia Tai Tianqing Pharmaceutical, Jiangsu Chia Tai Fenghai Pharmaceutical, Jiangsu Chia Tai Qingjiang Pharmaceutical, and invoX Pharma. These businesses form an important part of the group’s research, manufacturing, and commercial structure. Sino Biopharmaceutical’s therapeutic scope includes oncology, liver diseases, respiratory-system diseases, surgery, and analgesia. Its portfolio contains both biopharmaceutical and chemical products, indicating a business model that spans biologic and small-molecule medicine development and supply. The company’s activities are directed mainly toward the Chinese pharmaceutical market, where hospital medicines and specialist therapies are important components of pharmaceutical demand. The company’s visibility in equity markets increased through a series of index inclusions. In 2013, it was included in the MSCI Global Standard Indices and MSCI China Index. It became a constituent of the Hang Seng Index in 2018 and the Hang Seng China Enterprises Index in 2019. In 2020, it was included in the Hang Seng Connect Biotech 50 Index and the Hang Seng China (Hong Kong-listed) 25 Index. These changes marked the company’s growing representation in major China-related and Hong Kong-listed equity benchmarks. The available reference material does not supply a complete account of the group’s founding individuals, detailed corporate reorganizations, individual product histories, financial performance, or current leadership. Accordingly, those areas remain open for verification from company filings and annual reports. The documented history supports describing Sino Biopharmaceutical as an active, listed pharmaceutical conglomerate with a diversified Chinese therapeutic portfolio and a substantial subsidiary network.

• 2020

  Added to additional Hong Kong-listed and biotechnology indexes

  [1]Sino Biopharmaceutical Limited - Wikipediaen.wikipedia.org

  Sino Biopharmaceutical was included in the Hang Seng Connect Biotech 50 Index and the Hang Seng China (Hong Kong-listed) 25 Index.

• 2019

  Added to the Hang Seng China Enterprises Index

  [1]Sino Biopharmaceutical Limited - Wikipediaen.wikipedia.org

  The company was included in the Hang Seng China Enterprises Index.

• 2018

  Joined the Hang Seng Index

  [1]Sino Biopharmaceutical Limited - Wikipediaen.wikipedia.org

  Sino Biopharmaceutical became a constituent of the Hang Seng Index.

• 2013

  Added to MSCI China-related indices

  [1]Sino Biopharmaceutical Limited - Wikipediaen.wikipedia.org

  The company was included in the MSCI Global Standard Indices and the MSCI China Index.

• 2000

  Hong Kong listing

  [1]Sino Biopharmaceutical Limited - Wikipediaen.wikipedia.org

  Sino Biopharmaceutical was listed on the Hong Kong Stock Exchange, where it trades under ticker 1177.HK.

A large Chinese pharmaceutical group combining pharmaceutical research and development, manufacturing, and commercialization across specialty and hospital-focused therapeutic areas.

• Therapeutic area

  Oncology medicines

  Oncology is one of the therapeutic areas associated with Sino Biopharmaceutical’s portfolio. The group’s pharmaceutical businesses develop and commercialize medicines used in cancer treatment and related specialist-care settings. The available reference material does not identify a complete product list or provide enough information to describe individual brands, indications, or launch dates reliably.

• Therapeutic area

  Liver-disease medicines

  Medicines for liver diseases are a documented part of the group’s therapeutic scope. These products form part of Sino Biopharmaceutical’s specialist prescription portfolio in China. Public reference material supplied for this entry does not specify the individual products, formulations, regulatory milestones, or current commercial status of particular liver-disease brands.

• Therapeutic area

  Respiratory medicines

  The group also operates in respiratory-system medicines. This area is part of its broader hospital and prescription-drug business, alongside oncology and liver-disease treatments. The available material confirms the therapeutic category but does not provide sufficient product-level information to identify specific respiratory brands or launch chronology.

• Therapeutic area

  Surgical and analgesic medicines

  Sino Biopharmaceutical’s referenced product scope includes medicines used in surgery and analgesia. These products extend the group beyond chronic-disease and oncology treatments into hospital procedural and pain-management applications. Specific products, formulations, and markets are not detailed in the supplied sources.

• Product platform

  Biopharmaceuticals and chemical medicines

  The group’s overall portfolio includes both biopharmaceutical and chemical medicines. This combination supports a broad pharmaceutical platform incorporating biologic and small-molecule products, as well as innovative and established medicines. The reference material does not provide a sufficiently complete catalog to separate individual products or verify launch dates.

• 2026-08-19

  Sino Biopharmaceutical launches new global brand SBP Group[7]中国生物制药推出新全球品牌SBP Groupprnasia.com

  Reported: 2026-08-19

  Sino Biopharmaceutical Limited announced the launch of a new global brand, SBP Group, at its interim results briefing. SBP stands for Science, Breakthroughs and Patients, and the unified brand identity reflects the company's strategic evolution from a leading domestic biopharmaceutical company toward a global innovator.

• 2020-12-07

  Sinovac secures $515 million investment to support CoronaVac development and production[8]Sinovac获得5.15亿美元投资以支持CoronaVac研发和生产deccanherald.com

  Reported: 2020-12-07

  Sino Biopharmaceutical said a business unit would invest $515 million in Sinovac Life Sciences to help develop and produce CoronaVac. The investment would give Sino Biopharmaceutical a 15.03% interest in Sinovac Life Sciences.

• 2020-12-07

  Sinovac secures approximately $500 million in funding for COVID-19 vaccine development[9]Sinovac获得约5亿美元资金用于新冠疫苗研发businesstoday.in

  Reported: 2020-12-07

  Sinovac Biotech said it had secured approximately $500 million in funding for COVID-19 vaccine development. The company identified Sino Biopharmaceutical Ltd. as the investor.

• 2020-03-09

  Sino Biopharmaceutical obtains drug registration approval[10]中国生物制药获得药品注册批准sg.news.yahoo.com

  Reported: 2020-03-09

  Sino Biopharmaceutical reported that moxifloxacin hydrochloride and sodium chloride injection obtained drug registration approval from China’s National Medical Products Administration.

1. 1Sino Biopharmaceutical Limited - Wikipediaen.wikipedia.org
2. 2Sino Biopharmaceutical official websitesinobiopharm.com
3. 3中国生物制药：健康科技，温暖更多生命sbpgroup.com
4. 4中生概况-中国生物制药有限公司sbpgroup.com
5. 5创新产品-中国生物制药有限公司sbpgroup.com
6. 6管理团队-中国生物制药有限公司sbpgroup.com
7. 7中国生物制药推出新全球品牌SBP Groupprnasia.com
8. 8Sinovac获得5.15亿美元投资以支持CoronaVac研发和生产deccanherald.com
9. 9Sinovac获得约5亿美元资金用于新冠疫苗研发businesstoday.in
10. 10中国生物制药获得药品注册批准sg.news.yahoo.com
11. 11Sinovac secures $515 million funding to boost COVID-19 vaccine productionenglish.kontan.co.id
12. 12Sinovac secures $515m funding to boost COVID-19 vaccine production - Business - The Jakarta Postthejakartapost.com
13. 13Sinovac secures US$515m funding to boost Covid-19 vaccine productionbusinesstimes.com.sg